About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, February 18th, 2015

The QualityStocks
Daily Stock List


OncoSec Medical, Inc. (ONCS)

Wall Street Resources reported today on OncoSec Medical, Inc. (ONCS), PennyStocks24, Stock Analyzer, and Top Stock Picks did earlier, and we also highlight the Company, here at the QualityStocks Daily Newsletter.

San Diego, California-headquartered OncoSec Medical, Inc. is developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors. The bio-pharmaceutical Company’s mission is to pioneer and refine new electroporation technologies that endeavor to benefit patients and improve the quality of life for those whose skin cancers cannot be treated effectively with conventional treatment approaches. OncoSec Medical’s shares trade on the OTC Markets’ OTCQB.

The Company’s central technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immunocytokines. Clinical studies of ImmunoPulse have demonstrated positive safety and preliminary efficacy in the treatment of different skin cancers, and its potential to initiate a systemic immune response without the toxicities associated with many other systemic treatments. 

OncoSec Medical’s clinical programs include three Phase II clinical trials for ImmunoPulse targeting metastatic melanoma, Merkel cell carcinoma, and cutaneous T-cell lymphoma. Its lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is now in Phase 2 development, and is being conducted in collaboration with a number of prominent academic medical centers.

Additionally, OncoSec has its NeoPulse. It uses the OMS system to destroy cancer cells employing less harmful doses of bleomycin, a highly effective but also highly toxic anti-cancer drug. Clinical trial results suggest NeoPulse may enhance local activity of the anti-cancer drug bleomycin. This is while minimizing systemic side effects. Pre-clinical and clinical data from Phase 1 through Phase 4 clinical trials demonstrate NeoPulse technology holds promise as a treatment for solid tumors. This includes melanoma, basal cell carcinoma, squamous cell carcinoma, and liver and pancreatic cancers, with observable cancer cell destruction. 

ImmunoPulse and NeoPulse therapies represent a potential solution for less invasive and less expensive therapies that can lessen detrimental effects resulting from presently available cancer treatments. This includes surgery, systemic chemotherapy or immunotherapy, and other treatment alternatives.

Today, OncoSec Medical and Heat Biologics, Inc. (HTBX) announced that the two companies have entered into an agreement to evaluate the combination of the immunotherapy approaches developed by each company. Heat Biologics is a clinical stage biopharmaceutical company concentrating on the development of cancer immunotherapies. OncoSec Medical and Heat Biologics will jointly evaluate the preclinical efficacy of OncoSec’s core technology, ImmunoPulse, an investigational stage intratumoral DNA delivery platform, with Heat Biologics’ proprietary gp-96-Ig based ImPACT immunotherapy platform.

OncoSec Medical, Inc. (ONCS), closed Wednesday's trading session at $0.39, up 5.41%, on 875,858 volume with 193 trades. The average volume for the last 60 days is 1,071,026 and the stock's 52-week low/high is $0.3311/$0.97.

OriginOil, Inc. (OOIL)

Investor News Source, SuperStockTips, Stock Preacher, Penny Stocks Finder, InvestorSoup, Penny Stock Craze, Beacon Equity Research, Stock Commander, Stock Roach, StockHideout, PennyStockSpy, 007 Stock Chat, and AskSlapper reported on OriginOil, Inc. (OOIL), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

OriginOil, Inc. is the developer of an innovative energy production process for harvesting algae and cleaning up oil & gas water. This process operates at the first stage of extraction. The high-speed and chemical-free process can be embedded in other systems to improve performance. The Company has developed a unique process for removing up to 99 percent of contaminants from the very large quantities of water used by the oil & gas, algae, and other water-intensive industries. OriginOil is based in Los Angeles, California.

The foundation of the Company’s CLEAN-FRAC process is on its Electro Water Separation™ (EWS) technology. This technology efficiently removes oils, suspended solids, insoluble organics, and bacteria from produced or 'frac flowback' water, on a continuous flow basis and without the use of chemicals. EWS is the high-speed, chemical-free process to clean up large quantities of water.

The Company’s EWS works in two parts. First, contaminated water enters the first stage, Electro-Coagulation (EC). In this stage, electrical impulses are applied in long tubes, causing the organic contaminants to coagulate, or “clump” together. In 2009, OriginOil branded this stage Single-Step Extraction™. Second, the clumped-up material travels into a tank where electrical pulses generate a cloud of micro-bubbles that gently lifts the concentrate to the surface for harvesting.

CLEAN-FRAC™ is a complete solution. It can be designed for enhanced oil recovery, hydraulic fracturing operations, irrigation water, and potable water. It starts with OriginOil’s core EWS technology to remove oil, solids and bacteria, and adds downstream processes to achieve the desired result.

For the oil & gas industry, OriginOil is helping clean up produced water and recycle fracking water to reduce harm to the environment and lower costs. For the developing algae industry, it is making large-scale harvest possible. Moreover, in aquaculture, the Company is helping improve yields and making seafood healthier through substantially decreasing the levels of toxic ammonia and bacteria in water.

Yesterday, OriginOil announced that it launched the Smart Algae Harvester™ line of low-energy algae concentrators. The first model in the new line is the A25. This is a mainstay algae harvester designed for scale-up testing and initial production. A25 can process up to 25 liters per minute, or up to 36,000 liters (approximately 10,000 gallons) of algae cultivation water daily.

OriginOil, Inc. (OOIL), closed Wednesday's trading session at $0.095, up 9.20%, on 1,582,918 volume with 230 trades. The average volume for the last 60 days is 410,091 and the stock's 52-week low/high is $0.076/$0.25.

The Alkaline Water Company, Inc. (WTER)

SmallCapVoice, OTC Markets Group, MicroCap Gems, Investor Spec Sheet, Oakshire News Bulletin, and StreetAuthority Financial reported earlier on The Alkaline Water Company, Inc. (WTER), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

The Alkaline Water Company, Inc. has developed a unique, state-of-the-art, proprietary electrolysis beverage process that produces healthy alkaline water. This water is packaged and sold in 700ml, 1/2, 1, 3 liter and 1 gallon sizes under the trade name Alkaline88. It also sells in a 4-Pack case. Alkaline88's premier alkaline water is a pH balanced bottled alkaline drinking water enhanced with trace minerals and electrolytes. The Alkaline Water Company lists on the OTC Markets Group’s OTCQB. The Company has its corporate head office in Scottsdale, Arizona.

The Alkaline Water Company employs an advanced Electrochemically Activated Water (ECA) system to create 8.8 pH drinking water without the use of any chemicals. The ECA process uses specialized electronic cells coated with an array of rare earth minerals to produce scientifically engineered water.

The design of Alkaline88 is to encourage daily consumption of Alkaline Water by way of a consumer-oriented bulk delivery system aimed at removing expensive small bottles from the distribution supply chain. Alkaline88 is produced at an 8.8 pH, intended to obtain optimum body balance. It contains trace Himalayan minerals. The Company incorporated 84 beneficial trace Himalayan minerals to make alkaline88 particularly unique to other pH waters.

Earlier this month, The Alkaline Water Company announced that its 3 liter products have been accepted for distribution to many of the domestically operated Defense Commissary Agency Stores across the country. The Defense Commissary Agency (DeCA), based at Fort Lee, Virginia, is an agency of the Department of Defense (DoD), which operates over 245 commissaries globally.

Additionally, this month, the Company advised of continued eastward momentum with news of product placement at Pennsylvania-based Weis Markets, Inc. With this announcement, Alkaline88 is now available at more than 10,500 stores nationwide. This includes placement at 30 of the top 75 national retail grocers. Weis Markets comprises approximately 165 supermarkets with approximately 15,000 employees mainly located throughout Pennsylvania, and some regional operations in Maryland, New York, New Jersey, and West Virginia.

The Alkaline Water Company, Inc. (WTER), closed Wednesday's trading session at $0.1001, down 25.91%, on 1,489,561 volume with 191 trades. The average volume for the last 60 days is 286,960 and the stock's 52-week low/high is $0.0429/$0.438.

AtheroNova, Inc. (AHRO)

Streetwise Reports, RedChip, FeedBlitz, and UltimatePennyStock reported previously on AtheroNova, Inc. (AHRO), and we report on the Company today, here at the QualityStocks Daily Newsletter.

AtheroNova, Inc. (through its wholly-owned subsidiary, AtheroNova Operations, Inc.) is a biotechnology company with corporate headquarters in Irvine, California. Its’ emphasis is on the discovery, research, development, and licensing of novel compounds to safely reduce or regress atherosclerotic plaque deposits and improve lipid profiles in humans. AtheroNova’s shares trade on the OTC Markets’ OTCQB.

The Company’s plan is to develop - along with its lead compound AHRO-001 - multiple applications for its patented and patents-pending therapies in markets that include Cardiovascular Disease, Stroke, and Peripheral Artery Disease. All of these have been linked to atherosclerosis.

AHRO-001 is AtheroNova’s first novel application for the treatment and prevention of atherosclerosis. AHRO-001 has shown positive results in animal models for regression of plaque. It is undergoing human studies in pursuit of these same successful results.  

The AHRO delipidization process came about by co-inventors Dr. Giorgio Zadini and Dr. Filiberto Zadini. Their research is covered by AHRO patent applications. The AHRO delipidization process dissolves plaques in artery walls so they are removed via normal body processes. AHRO-001 penetrates through the atherosclerotic fibrous cap and, through delipidization, causes quick reduction in the size of the deposits of soft vulnerable plaque in an artery's walls.  

AtheroNova is developing AHRO-001 to directly compete with statins that largely lower cholesterol and stabilize plaque. AHRO-001, in preclinical studies, did not show adverse effects. AHRO-001 was also well tolerated at high doses.

Regarding pre-clinical studies, AtheroNova successfully completed preclinical studies at UCLA and Cedars‐Sinai. In these studies, use of AHRO-001 led to a 95 percent reduction in innominate arterial plaque formation in comparison to the control group.

Last week, AtheroNova announced that it received a Notice of Issuance of Patent No. 8952067 titled "Subcutaneous Fat Reduction" by the United States Patent and Trade Office (USPTO) with an expiration date of June 20, 2032.

AtheroNova, Inc. (AHRO), closed Wednesday's trading session at $0.0744, up 65.33%, on 1,671,336 volume with 204 trades. The average volume for the last 60 days is 70,126 and the stock's 52-week low/high is $0.0415/$5.45.

Inergetics, Inc. (NRTI)

SmallCapVoice and Zacks reported on Inergetics, Inc. (NRTI), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Inergetics, Inc. is a foremost developer of patented nutritional products consisting of high-quality ingredients and proprietary formulations. It has targeted brands that independently serve the Clinical Nutrition, Long Term Care (Senior Care), and Sports Nutrition Markets. Inergetics has entered into a strategic partnership with Terra Tech Corp. (TRTC) to jointly develop a line of natural Cannibidiol based nutritional supplements. Terra Tech is an urban agricultural company. Inergetics is based in Newark, New Jersey.

The Company’s brand portfolio features Martha Stewart Essentials™. This is a complete line of whole-food based supplements created expressly for women, developed in association with Martha Stewart herself.

In addition, Inergetics’ brands include Surgex® Sports Nutrition, which is the preferred nutritional supplement of Army Sports. Its Surgex® Sports Nutrition is a clinically studied performance enhancing formula. The design of it is to build lean muscle and increase energy to realize top levels of power and stamina. Surgex® Sports Nutrition features novel formulas developed to meet the nutritional needs of the masses and amateur and professional athletes.  

Furthermore, Inergetics’ brands include Bikini Ready®. Bikini Ready® is its comprehensive line of weight loss lifestyle products. Bikini Ready® products include Weight Loss Catalyst, Fashion Multi, Cleanse, and Yummy Shake Flavors, all specifically designed for women.

Inergetics also offers SlimTrim™, which is an affordable, premium value diet brand. The formulation of SlimTrim™ is to work with one’s body naturally in combination with diet and exercise. The design of SlimTrim™ is to help one lose weight, burn fat, stimulate metabolism, cleanse, and also curb appetite.

The Company also has its OmEssentials®. This is a line of scientifically advanced nutritional supplements designed to further the health and wellness of yoga practitioners and active individuals.

Yesterday, Inergetics announced that the official launch event for its new Cannabidiol (CBD)-based product will take place on March 26, 2015 at the Bouley Botanical in TriBeCa, New York City. Details on Inergetics’ first CBD-based nutraceutical supplement, including branding and distribution will be announced at the invitation-only event for shareholders, the investment community, as well as the news media.

Inergetics, Inc. (NRTI), closed Wednesday's trading session at $0.0189, down 5.50%, on 3,075,033 volume with 69 trades. The average volume for the last 60 days is 1,883,236 and the stock's 52-week low/high is $0.0082/$0.34.

PositiveID Corp. (PSID)

Greenbackers, Penny Pick Finders, OTPicks, PennyStockProphet, Planet Penny Stocks, Buzz Stocks, SmallCapVoice, PennyStocks24, SecretStockPromo, Stock Onion, Stock Preacher, Penny Stock Craze, Penny Stocks Finder, InvestorSoup, Beacon Equity Research, StockHideout, and SuperStockTips reported this month on PositiveID Corp. (PSID), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Delray Beach, Florida-based PositiveID Corp. is a developer of biological detection and diagnostics solutions. The Company is a developer of biological detection systems for the Unites States’ homeland defense industry and rapid biological testing. PositiveID’s emphasis is on the development of microfluidic systems for the automated preparation of and performance of biological assays to detect biological threats at high-value locations and analyze samples in a medical environment. The Company lists on the OTCQB.

In May of 2011, PositiveID acquired MicroFluidic Systems (MFS). MFS specializes in the development and production of automated instruments for detecting and processing biological samples. MFS' core technology is used for airborne pathogen detection, rapid clinical diagnostics, as well as sample preparation applications.

Concerning Molecular Diagnostics, PositiveID’s products include M-BAND and Firefly. The Microfluidics-based Bioagent Networked Detector (M-BAND) developed by MFS is a bioaerosol monitor with fully integrated systems with sample collection, processing, and detection modules.

PositiveID is developing the Firefly Dx detection system. Firefly DX is its real-time, hand held, polymerase chain reaction (PCR) pathogen detection system. This system is a two-part device and it consists of a portable handheld instrument with wireless Bluetooth communication and disposable single-use cartridges containing all vital analytical elements.

Last week, PositiveID announced that it reached a major milestone in the development of its handheld Firefly Dx system with the completion of the build of its breadboard PCR (polymerase chain reaction) chip. The Company has commenced testing assays to prove the design of achieving PCR results in under 20 minutes at standard laboratory volumes, versus existing technologies that necessitate lab-based equipment and can take hours or days to provide results.

PositiveID’s plan is to announce the results of its testing as it is completed over the next several months. The Company is developing Firefly Dx based on intellectual property (IP) and knowledge gained during years of development and $30 million of contract funding from the U.S. Department of Homeland Security for its M-BAND system, which uses PCR for the identification of airborne bio-threats.

PositiveID Corp. (PSID), closed Wednesday's trading session at $0.0259, up 10.21%, on 7,307,060 volume with 368 trades. The average volume for the last 60 days is 1,704,182 and the stock's 52-week low/high is $0.021/$0.125.

Entia Biosciences, Inc. (ERGO)

SmallCapVoice reported previously on Entia Biosciences, Inc. (ERGO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Entia Biosciences, Inc. is an emerging leader in the field of Nutrigenomics. The Company is an authority on the clinical effects of oxidative stress and free radical reactions. Entia Biosciences is bringing this expertise to the fields of food science biotechnology and Nutrigenomics. Entia identifies, scientifically validates, patents, and commercializes solutions that address multi-billion dollar markets for health, beauty, and agriculture.

The Company is headquartered in Sherwood, Oregon. It previously went by the name Total Nutraceutical Solutions, Inc. It changed its name to Entia Biosciences, Inc. in January of 2012. Founded in 2007. Entia Biosciences lists on the OTCQB.

The Company’s growing portfolio of intellectual property (IP) presently covers some of the most powerful antioxidants and bio-nutrients occurring in nature. Its ErgoD2 line of Medical Foods provide for the safe daily nutritional management of a host of autoimmune and neurodegenerative diseases. ErgoD2's ingredients are natural food-based dietary ingredients proven effective in helping to manage specific disease or dysfunctions.

Entia Biosciences’ ErgoD2® technology aims to treat anemia through stabilizing iron levels, reducing inflammation, and boosting the internal antioxidant system. ErgoD2®is a proprietary pharmaceutical grade organic compound from whole food. It contains the micro-nutrients L-Ergothioneine, an amino acid with a dedicated transporter (SLC22A4), and Ergocalciferol (vitamin D2). These nutrients are naturally enhanced and concentrated to therapeutic levels using the Company’s patented technology.

At the heart of this technology are the aforementioned L-Ergothioneine and Ergocalciferol. In clinical studies conducted by the Company in diabetes and chronic kidney disease, these have been shown to stimulate iron export from the cell.

This past November, Entia Biosciences’ Marvin S. Hausman MD, CEO, spoke on the subject - "Treatment of Anemia with a Natural Mushroom-Based Medical Food ErgoD2." The 17th International Conference of FFC, Discovery, Utilization, and Control of Bioactive Components and Functional Foods took place from November 18-19, 2014, at the University of San Diego (San Diego, California).

Entia Biosciences, Inc. (ERGO), closed Wednesday's trading session at $0.162, up 18.25%, on 334,461 volume with 10 trades. The average volume for the last 60 days is 39,339 and the stock's 52-week low/high is $0.13/$0.75.


The QualityStocks
Company Corner


One World Holdings, Inc. (OWOO)

The QualityStocks Daily Newsletter would like to spotlight One World Holdings, Inc. (OWOO). Today, One World Holdings, Inc. closed trading at $0.0051, off by 12.07%, on 4,444,627 volume with 79 trades. The stock’s average daily volume over the past 60 days is 4,136,036, and its 52-week low/high is $0.0008/$0.2998.

One World Holdings, Inc. subsidiary, The One World Doll Project, announced today that the company and its doll designer, Stacey McBride-Irby were featured in the February 17th edition of The Huffington Post. "After having a successful showing at Toy Fair 2015, I am very excited the Huffington Post contributor, Laura Dunn chose to spotlight my story," stated Ms. McBride-Irby. "As an African-American business woman I enjoy the opportunity of being able to encourage other women to seize opportunities, take risks and embrace their ability to empower themselves through entrepreneurship," she added.

One World Holdings, Inc. (OWOO) subsidiary, The One World Doll Project, was established in 2010 to make a significant positive cultural impact through the doll category, transcending global and ethnic borders to create positive self-image in young women and girl around the world. Led by worldwide famous doll designer Stacy McBride-Irby, The One World Doll Project team has more than 50 collective years in the doll and toy industry and is dedicated and armed with the experience to ensure that the dolls are of the highest quality and value.

In 2013, the company released its Prettie Girls!™ line of multi-cultural fashion dolls uniquely designed with individual physical attributes, personal stories and hobbies, and goals and inspirations. For young girls, the dolls are a friend, a partner in play, and a glimpse of their biggest, brightest dreams. For young women, the dolls are a symbol of who they are and what they can achieve. For doll connoisseurs, The One World Doll Project promises stylish works of art that will become a vital part of a growing collectors’ market.

The One World Doll Project also has a Signature Celebrity Collection of Prettie Girls! and in 2013 released its first celebrity collectors doll modeled after supermodel Cynthia Bailey from The Real Housewives of Atlanta. Since the release of the doll, it has been showcased with Synthia on The Arsenio Hall Show, What Happens Live with Andy Cohen and The Bethenny Show.

Using a web-based sales model, One World Holdings plans to quickly capture significant market share in the dolls and stuffed toys space. After securing a strong online presence, the company will focus on brick and mortar retailing as it moves toward the ultimate pursuit of expanding worldwide. The company has established distribution deals with Toys “R” Us, HEB, dollgenie.com, Tuckers Toy Shop, pattycakedoll.com, and has recently expanded its retail presence internationally with the People’s Pharmacy storechain in the Central American country of Belize. The Prettie Girls! Dolls have been featured in national and international media spotlights like CNN, The Wall Street Journal, Jet Magazine, Bloomberg.com, Parade.com, Dolls Magazine, The Toy Book, The Houston Chronicle and Houston Business Journal, and TheStreet.com. Disclaimer

One World Holdings, Inc. Company Blog

One World Holdings, Inc. News:

The One World Doll Project and Doll Designer, Stacey Mcbride-Irby Featured in Huffington Post

The One World Doll Project Founder Interviews With CEOLIVE.TV; Updates on Toy Fair 2015

The One World Doll Project Founder Interviews With CEOLIVE.TV; Updates on Amazon.com Deal, 2015 Product Line Expansion and Toy Fair

Pure Hospitality Solutions, Inc. (PNOW)

The QualityStocks Daily Newsletter would like to spotlight Pure Hospitality Solutions, Inc. (PNOW). Today, Pure Hospitality Solutions, Inc. closed trading at $0.021, up 103.88%, on 160,213 volume with 10 trades. The stock’s average daily volume over the past 60 days is 100,772, and its 52-week low/high is $0.0031/$0.9412.

Pure Hospitality Solutions, Inc. (PNOW) is a provider of proprietary technology, marketing solutions, infrastructure and branding services to hotel operators.

The company's innovative platform functions as a powerful vehicle to help hotel operators achieve greater success in three specific areas: (i) expanded international exposure and recognition, (ii) powerful core structure, and (iii) high occupancy rates that drive increases in bottom-line profits. Pure continuously refines its suite of proprietary solutions to deliver measurable and proven results to hotel properties. This success has been reflected in those properties operating under the Hotel PURE brand as well as with independent boutique hotel properties utilizing the company's Friendly Reservation Online (FROL) booking engine technology and internet marketing services.

Operating a successful bi-lateral business model, Pure has four objectives:

1. To franchise the Hotel PURE brand to selected hotel properties worldwide similar to the business model currently employed by Big Brand operators such as Holiday Inn, Marriott, Sheraton and others;

2. Provide highly efficient and economical back-end booking engine technology services to independently branded boutique hotels that require a robust online presence;

3. Launch a stand-alone online hotel booking search engine primarily focused on Central America; and,

4. Expand the portfolio of Pure-owned boutique hotels operating under the Hotel PURE brand.

The company initially began growing its operations primarily in the United States. However most recently, major opportunities in Central America began presenting themselves, giving Oriens the ability to retool its business model. Now the company is positioned to acquire, own and operate its own properties – which would be marketed under the new brand with occupancies handled by the re-launched online booking engine system.

Ultimately, Pure intends to become a top-tier hotel brand operator and Internet booking and marketing service provider, qualifying as a preferred supplier to lending institutions. The company also intends to establish an invaluable international footprint with its online booking engine technology and marketing offerings; making that segment of its business a prime acquisition target for major online travel search and booking engine companies. Advancement toward this goal is guided by an executive management team with deep expertise in technology, banking, management, hospitality, branding and marketing, technical development and more. Disclaimer

Pure Hospitality Solutions, Inc. Company Blog

Pure Hospitality Solutions, Inc. News:

Pure Expands Oveedia, Aligns With Sabre Travel Network

PURE Hospitality Solutions Launches Non-Toxic Funding Campaign for Oveedia

PURE Hospitality Solutions Retains StartX Software Consulting; Oveedia Interactive Infrastructure

MIT Holding (MITD)

The QualityStocks Daily Newsletter would like to spotlight MIT Holding (MITD). Today, MIT Holding closed trading at $0.095, up 18.60%, on 20,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 20,283, and its 52-week low/high is $0.032/$0.31.

MIT Holding (MITD), through its agents, facilitators and contractual obligations, offers professional outpatient medical care with ambulatory infusion therapies, home infusion services, and medical equipment delivery. The company is also pursuing government contacts to obtain approval to import pharmaceutical products into the Americas.

In support of these core services, MIT Holding provides expert legal, accounting, advisory and educational services to physicians, medical centers, hospitals, small and large businesses regarding the Affordable Care Act; offers travel and transportation services of medically challenged patients for medical needs and personal travel; and through its contracts is approved to, conduct and administer FDA clinical trials.

Collectively, these services contribute to MIT Holding’s strategy to provide custom prescription solutions in a variety of methods and generate multiple revenue streams. Following a successful reorganization initiative in January, 2014, MIT Holding is positioned to achieve 32% minimum net profits and has maintained profitability in its fiscal second and third quarters. This profitability validates the company’s business model and its approach to the evolving Affordable Health Care Act and its impact on the health services industry.

MIT Holding meets and/or exceeds major U.S. health insurance requirements and is therefore able to direct bill and receive payments from carriers on behalf of the patient its agents and its facilitators. This ability marks an important step in the company’s goal of developing the first-of-its-kind seamless transition for patient needs from hospital discharge to complete home recovery. This and other corporate initiatives are spearheaded by a management team committed to building shareholder value, revenues and corporate expansion while providing viable solutions to the perpetual changes in the health care sector. Disclaimer

MIT Holding Company Blog

MIT Holding News:

MIT Holding (MITD) Launches New Website with Investor Relations Suite

MIT Holding, Inc. Names Tommy J. Duncan as President

MIT Holding, Inc. (MITD) Announces Engagement of QualityStocks Investor Relations Services

Boreal Water Collection, Inc. (BRWC)

The QualityStocks Daily Newsletter would like to spotlight Boreal Water Collection, Inc. (BRWC). Today, Boreal Water Collection, Inc. closed trading at $0.0025, up 25.00%, on 195,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 828,663, and its 52-week low/high is $0.002/$0.03.

Boreal Water Collection, Inc. (BRWC) is an established water bottler of premium private-labeled bottled water products tailored for each client’s particular need, be it publicity, promotion, marketing, internal use or a specific event. This emphasis on customization and quality has earned Boreal an impressive reputation, evidenced by its prestigious customer base of high-end beverage brands, retailer channels, high-end hotels and restaurant chains such as H&M, Mercedes, W Hotels, Dean & Deluca, Fred Water, Wat-aah, Saks Fifth Ave, Balance Water, NY Quin Hotel, Bouchon Bakery and Princeton University, just to name a few!

Located 90 miles north New York City, Boreal’s plant is only 17 miles from its well-protected source of natural spring water, a pristine and abundant spring source deep inside the heart of the Catskill Mountains. The spring’s exceptional geological and geographical features have created the perfect environment for Boreal’s low-mineral, sodium-free and well-balanced PH water. With exclusive exploitation rights, Boreal has a confirmed volume in excess of thousands of millions of gallons.

Boreal offers a line of award-winning water products, including functional enhanced water, infused water, carbonated water, vitamins enhanced water, flavored still or sparkling, minerals enhanced water, oxygenated water, electrolyte water, distilled water, alkaline water, caffeinated water and natural spring water.

Accommodating this plentiful water supply and range of product offerings, Boreal has established a 75,000-square foot manufacturing facility. Boreal can process a full range of water and bottle types and has the most creative staff for all private labeling needs. The company offers fully integrated turnkey service, made-to-order labeling along with distinctive water bottles. In short, Boreal is a “Boutique Bottler” and is focusing on becoming the leader of this attractive niche of the growing multi-billion dollar bottled water industry. Disclaimer

Boreal Water Collection, Inc. Company Blog

Boreal Water Collection, Inc. News:

Boreal Water Collection to Exhibit at China's Largest Food Show

Boreal Water Collection Reports Continued Growth in the Third Quarter of 2014, Sales Increase by 14% While Profitability Rises by 57%

The Chatwal Hotel (NY) Agrees to Have Boreal Water Collection Produce Their Private Labeled Bottled Water

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.006, even for the day, on 229,500 volume with 3 trades. The stock’s average daily volume over the past 60 days is 72,525, and its 52-week low/high is $0.0016/$0.018.

Consorteum Holdings, Inc. (CSRH) has spent the last 3 years developing relationships and licensing agreements to take the center stage in the emerging market of mobile gaming. The company has the capability to deliver rich mobile content to end users who will use their smart phones in ways that could not even have been imagined five years ago.

Specializing in delivery of mobile content, mobile payment solutions and products through a mix of on-deck partnerships, license agreements, and joint venture revenue share arrangements, the company operates as a technology and services aggregator to meet the diverse needs of its client base. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.

ThreeFiftyNine Inc., a wholly owned subsidiary, hired a software development team that had previously designed the world’s first regulatory compliant mobile platform for delivery of gaming content created by a third party. The platform, which has met the rigorous standards of the Nevada Gaming Board, the gold standard in regulatory gaming, represents the first generation software delivery platform for mobile devices. The development team spent the past 5 years and millions of dollars in non-recurring engineering costs to complete the development of the platform. At the heart is the capability to deliver any digital content across any cellular network to any mobile device. This key differentiator makes it possible for Consorteum to approach many different markets that are in the business of providing mobile connectivity and mobile content.

Consorteum’s mobile initiatives will benefit multiple business verticals. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer

Consorteum Holdings, Inc. Company Blog

Consorteum Holdings, Inc. News:

Consorteum Holdings Signs License Agreement With NYG Holdings

Consorteum Holdings Signs Mobile Application Development Contract With Bet Butler Limited

Consorteum Holdings Launches New Mobile Results App for Popular Keno Game

WordLogic Corp. (WLGC)

The QualityStocks Daily Newsletter would like to spotlight WordLogic Corp. (WLGC). Today, WordLogic Corp. closed trading at $0.06, even for the day, on 75,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 40,667, and its 52-week low/high is $0.0462/$0.235.

WordLogic Corp. (WLGC) leverages more than 10 years of advanced R&D to assume its position as a global leader in predictive text input technology. Backed by multiple patents and its predictive engine, WordLogic’s interface is revolutionizing the way individuals and businesses search and communicate on touch screen devices. Furthermore, WordLogic offers a range of licensing options of its technology and patent portfolio.

The company’s technology incorporates proprietary Gesturing™ and WordChunking™ features that accelerate typing speeds while reducing the effort needed for accuracy. This interface increased text input on mobile devices by five times, rapidly speeding communication via instant messaging, text messaging, captioning, email and information searching. The iKnowU® keyboard uses state-of-the-art patented technology that becomes more accurate with each use, constantly learning about the user’s style and preferences. Utilizing the WordChunking and Gesturing, iKnowU enables the user to chain together phrases and create whole sentences in a matter of seconds.

For the business realm, WordLogic has developed a unique cloud solution to fit the specific needs of multiple industry sectors, enabling enterprises to create a single cloud-based dictionary specific to the company’s realm of expertise or multiple dictionaries specific for individual specialties or departments. This cloud solution creates continuity for users across multiple devices, boosting accuracy and productivity. WordLogic Reach™ enables users to select and insert meeting plans, contact information, and calendar entries from other apps in the mobile device.

Frost & Sullivan recently recognized WordLogic as the recipient of the 2014 North American Enabling Technology Leadership Award for Predictive Keyboard Applications, saying, “WordLogic’s technically impressive product - WordLogic Predictive Engine and its associated products iKnowU® and Reach™ - offers key competitive advantages, such as market-leading word and phrase prediction capabilities, a context-aware advertising model; simpler integration, increased speed and accuracy; and reduced costs. Add to that the significant number of pending and issued patents and you can see how value a package of technology WordLogic has developed truly is.” Disclaimer

WordLogic Corp. Company Blog

WordLogic Corp. News:

WordLogic Corp. (WLGC) Inks Deal to Monetize Intellectual Property for General Electric (GE)

WordLogic (OTCQB:WLGC) Announces that Apple Approves the Launch of an iOS8 Version of the iKnowU Keyboard

WordLogic the Sale of Exclusive Rights to Legal Enterprise Solutions to Private Equity Group

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.0583, off by 3.32%, on 1,375,727 volume with 47 trades. The stock’s average daily volume over the past 60 days is 590,886, and its 52-week low/high is $0.0555/$0.255.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.

The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.

In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corporation Announces Completion of Cell Bank for Parkinson's Disease Clinical Trial

International Stem Cell Corporation to Conduct Parkinson's Disease Clinical Study in Australia

International Stem Cell Corporation to Present at Biotech Showcase(TM) 2015


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters





1-2-3 Stock Alerts


Wall Street Resources

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251